Eight Advisory carried out the financial and tax buy-side due diligence of Laboratoire XO in the context of its acquisition by Novalpina

18 November 2020

‹ Back to presse releases

Eight Advisory has been mandated by Novalpina to carry out the financial and tax buy-side due diligence of Laboratoire XO.

Laboratoire XO is a French pharmaceutical company founded in 2015, based in Saint-Cloud, and specialized in the production and distribution of prescription drugs for the treatment of chronic diseases. It achieved sales of 46 million euros in 2019.

Novalpina Capital, a UK-based private equity firm, acquires a majority stake in Laboratoire XO’s pharmaceutical business.

This transaction, which values the company at more than 300 million euros, aims to accelerate growth with an aggressive European acquisition strategy in order to develop a larger product portfolio.

Eight Advisory carried out the financial buy-side due diligence, the team was composed of Gennat Mouline, Alison Harutunian and Numa Agnan.

Eight Advisory Avocats carried out the tax buy-side due diligence, the team was composed of Guillaume Rembry and Guillaume Exerjean.